Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Phase II multi-chort, adaptive two-stage, open label, nonrandomized study. The aim of our
study is to evaluate the efficacy and safety of anti-PD-1 antibody SHR-1210(Camrelizumab) in
combination with a small-molecule multikinase inhibitor Famitinib in subjects with advanced
RCC/UC/CC/EC and recurrent OC.
chort1: Renal Cell Carcinoma (RCC) chort2: Urothelial Carcinoma(UC) chort3: Ovarian Cancer
(OC) chort4: Cervical Cancer (CC) chort5: Endometrial Cancer (EC)